Development of Key Technologies to Treat Aortic Aneurysms

该项目的目标是腹主动脉瘤的治疗，腹主动脉瘤是一种致命的病理，最常见于60多岁的男性。它将隆巴德医疗公司的临床和医疗植入技术与Microport在医疗器械制造技术方面的专业知识结合在一起。这项计划将开发一种微创植入物，可用于日间动脉瘤手术。这将为世界各地的医疗保健系统节省资金，并使患者能够尽快回家并恢复正常生活。通过投资于前所未有的制造自动化水平，这些公司预计能够在不增加医疗保健提供者成本的情况下提供这种治疗益处。动脉瘤的日间手术目前还处于试验性阶段，治疗动脉瘤的微创植入物几乎完全是手工制作的。该项目的目标是在临床和制造技术方面采取重大步骤。

This project targets the treatment of abdominal aortic aneurysms; a fatal pathology most common in men in their mid sixties. It combines the clinical and medical implant skills of Lombard Medical with Microport's expertise in medical device manufacturing technology. This progam will develop a minimally invasive implant that can be used in day-case aneurysm surgery. This will save money for healthcare system world-wide and allow patients to return home and to a normal life as rapidly as possible. By investing in unprecedented levels of manufacturing automation, the companies expect to be able to deliver this therapeutic benefit at no additional cost to healthcare providers. Day case surgery for aneurysms is currently experimental and minimally invasive implants to treat aneurysms are almost completely hand-made. This project aims to take dramatic steps in both clinical and manufacturing technology.